(Lymphoma) Opdivo (Nivolumab) Approved for Pediatric Patients with Hodgkin Lymphoma in Japan

• October 4, 2021
• 1 min read

On September 27, 2021, Ono Pharmaceutical announced that Opdivo (nivolumab), an immune checkpoint inhibitor, received approval in Japan for use in pediatric patients aged 1 year and older with refractory or relapsed Hodgkin lymphoma. This marks the first approval of an immune checkpoint inhibitor for pediatric cancer patients in Japan.

Approximately 1,720 cases of Hodgkin lymphoma are diagnosed annually in Japan, of which approximately 70 are pediatric patients. Adult patients had previously been approved to receive Opdivo treatment.

Source: https://www.sankei.com/article/20210927-O4FZHJV26BK25FRPKLROEKTGO4/

Lymphoma | Immunotherapy | Pediatric | Nivolumab

• Immunotherapy

• Clinical Trial Medications

  • (Lung Cancer) Phase II results for Topotecan and Topotecan + Berzosertib combination.
  • (Lung Cancer) Efficacy of Enhertu in HER2-mutant non-small cell lung cancer (NSCLC).
  • (Lung Cancer) Clinical outcomes of anti-B7-H3 antibody-drug conjugate DS-7300.

Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).

Figure 1

Figure 2

Figure 3

Figure 4